Publications
- Komentář ke studii2023 | First Faculty of Medicine
- G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial2022 | First Faculty of Medicine, Faculty of Mathematics and Physics
- Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways2022 | First Faculty of Medicine
- Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents2022 | First Faculty of Medicine
- Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1(C1120T) Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry2020 | First Faculty of Medicine
- Randomizovaná otevřená akademická studie: srovnání standardního podání azacytidinu oproti azacytidinu s preinkubací G-CSF u myelodysplastického syndromu vyššího rizika - interim analýza2019 | First Faculty of Medicine, Faculty of Mathematics and Physics, Faculty of Physical Education and Sport
- NQO1*2 polymorphism predicts overall survival in MDS patients2019 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Azacitidine Switch to Lenalidomide Eradicated the TP53/ CDKN2A Co-Mutated Clone and Induced Long-Term Erythroid Response in Del(5q) MDS2019 | First Faculty of Medicine
- Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)2018 | First Faculty of Medicine
- MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia2017 | First Faculty of Medicine, Faculty of Mathematics and Physics
Loading network view...
